Fulcrum Therapeutics Inc (FULC) Stock Analysis

Fulcrum Therapeutics Inc (FULC) is a publicly traded company in the HEALTHCARE sector. It trades at $3.14, carries a market capitalization of $427.79M. This page summarizes the public market data, fundamentals, and frequently asked questions for FULC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Fulcrum Therapeutics Inc currently has a Bearish sentiment score of -0.70.

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for genetically defined diseases with pressing unmet medical needs. The company boasts a robust pipeline, particularly targeting conditions like Duchenne Muscular Dystrophy, and is committed to transforming patient care through precision medicine. Leveraging its proprietary drug discovery platform, Fulcrum is strategically positioned to not onl...

GNG Research Analysis

GNG Research scores Fulcrum Therapeutics Inc (FULC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FULC.

Frequently Asked Questions

Does FULC pay dividends?

Fulcrum Therapeutics Inc (FULC) does not currently pay a regular dividend.

What is FULC's market cap?

Fulcrum Therapeutics Inc (FULC) has a market capitalization of $427.79M with a current stock price of $3.14.